CRVS
Corvus Pharmaceuticals Inc

6,100
Mkt Cap
$657.95M
Volume
1.27M
52W High
$9.32
52W Low
$2.54
PE Ratio
-16.47
CRVS Fundamentals
Price
$8.81
Prev Close
$8.81
Open
$8.89
50D MA
$7.80
Beta
1.47
Avg. Volume
966,260.42
EPS (Annual)
-$1.02
P/B
9.17
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS
Foresite Capital Management VI LLC lifted its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 9.5% in the 2nd quarter, according to its most recent disclosure with...
MarketBeat·9d ago
News Placeholder
BML Capital Management LLC Buys New Stake in Corvus Pharmaceuticals, Inc. $CRVS
BML Capital Management LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·18d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 7.4% - Still a Buy?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.4% Higher - What's Next...
MarketBeat·20d ago
News Placeholder
Cantor Fitzgerald Issues Positive Forecast for CRVS Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2026 EPS estimates for Corvus Pharmaceuticals in a research note issued to...
MarketBeat·27d ago
News Placeholder
What is HC Wainwright's Estimate for CRVS FY2025 Earnings?
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at HC Wainwright upped their FY2025 EPS estimates for Corvus Pharmaceuticals in a research note issued on Wednesday, November 5th...
MarketBeat·27d ago
News Placeholder
Wall Street Zen Upgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to "Hold"
Wall Street Zen raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·28d ago
News Placeholder
HC Wainwright Has Bearish Forecast for CRVS FY2028 Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released...
MarketBeat·28d ago
News Placeholder
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are covering the stock...
MarketBeat·29d ago
News Placeholder
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...
PR Newswire·2mo ago

Latest CRVS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.